Novo Nordisk has entered into a definitive agreement to acquire Forma Therapeutics for $1.1 billion in cash. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and rare blood disorders.   The acquisition includes Forma’s lead development candidate, etavopivat, adding to Novo Nordisk’s pipeline in hemoglobinopathies, a group of disorders in which there is abnormal production or structure of the hemoglobin protein in the red blood cells. Etav...